JP2024510260A5 - - Google Patents
Info
- Publication number
- JP2024510260A5 JP2024510260A5 JP2023556949A JP2023556949A JP2024510260A5 JP 2024510260 A5 JP2024510260 A5 JP 2024510260A5 JP 2023556949 A JP2023556949 A JP 2023556949A JP 2023556949 A JP2023556949 A JP 2023556949A JP 2024510260 A5 JP2024510260 A5 JP 2024510260A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- acth
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025157498A JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163310P | 2021-03-19 | 2021-03-19 | |
| US63/163,310 | 2021-03-19 | ||
| US202263298571P | 2022-01-11 | 2022-01-11 | |
| US63/298,571 | 2022-01-11 | ||
| PCT/US2022/020543 WO2022197798A1 (en) | 2021-03-19 | 2022-03-16 | Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025157498A Division JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510260A JP2024510260A (ja) | 2024-03-06 |
| JP2024510260A5 true JP2024510260A5 (enExample) | 2025-10-01 |
Family
ID=83321094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556949A Pending JP2024510260A (ja) | 2021-03-19 | 2022-03-16 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
| JP2025157498A Pending JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025157498A Pending JP2026009936A (ja) | 2021-03-19 | 2025-09-22 | 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12280046B2 (enExample) |
| EP (1) | EP4308553A4 (enExample) |
| JP (2) | JP2024510260A (enExample) |
| KR (1) | KR20230159443A (enExample) |
| AU (1) | AU2022240609A1 (enExample) |
| BR (1) | BR112023018816A2 (enExample) |
| CA (1) | CA3211644A1 (enExample) |
| IL (1) | IL305952A (enExample) |
| MX (1) | MX2023010897A (enExample) |
| TW (1) | TWI916531B (enExample) |
| WO (1) | WO2022197798A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102695210B1 (ko) | 2018-06-05 | 2024-08-13 | 크리네틱스 파마슈티칼스, 인크. | 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도 |
| BR112023018816A2 (pt) | 2021-03-19 | 2023-10-31 | Crinetics Pharmaceuticals Inc | Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença |
| EP4634176A1 (en) * | 2022-12-16 | 2025-10-22 | Crinetics Pharmaceuticals, Inc. | Crystalline melanocortin subtype-2 receptor (mc2r) antagonist |
| PE20260134A1 (es) * | 2023-05-19 | 2026-01-21 | Crinetics Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de la hiperplasia suprarrenal congenita |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284956A (en) | 1988-09-06 | 1994-02-08 | Hoffmann-La Roche Inc. | Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| US6890940B2 (en) | 2001-06-29 | 2005-05-10 | Kowa Co., Ltd. | Bis(2-aryl-5-pyridyl) derivatives |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US20030158209A1 (en) | 2001-10-09 | 2003-08-21 | Neurocrine Biosciences Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US6664273B2 (en) | 2001-11-26 | 2003-12-16 | Schering Corporation | Piperidine based MCH antagonists for treatment of obesity and CNS disorders |
| US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| WO2003068738A1 (en) | 2002-02-11 | 2003-08-21 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
| JP2005534632A (ja) | 2002-05-10 | 2005-11-17 | ニューロクライン バイオサイエンセズ， インコーポレイテッド | メラノコルチンレセプターリガンドとしての置換ピペラジン |
| WO2004081643A1 (en) | 2002-12-20 | 2004-09-23 | Kaiser Aerospace & Electronics Corp. | Lenslet array with polarization conversion |
| EP1460073A1 (en) | 2003-03-20 | 2004-09-22 | MyoContract Ltd. | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| NZ544820A (en) | 2003-08-11 | 2009-02-28 | Hoffmann La Roche | Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors |
| EP1663232B1 (en) | 2003-09-09 | 2007-10-03 | F. Hoffmann-La Roche Ag | 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20050119252A1 (en) | 2003-10-22 | 2005-06-02 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US20050192286A1 (en) | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| CA2625877A1 (en) | 2005-10-18 | 2007-04-26 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| RU2303597C1 (ru) | 2006-05-12 | 2007-07-27 | Иващенко Андрей Александрович | Фармацевтическая композиция, способы ее получения и применения |
| KR101088239B1 (ko) | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘 |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| PT2344474E (pt) | 2008-09-02 | 2015-12-28 | Novartis Ag | Derivados de picolinamida como inibidores de cinase |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PE20120693A1 (es) | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| EP2715754B1 (en) | 2011-05-31 | 2015-07-29 | Linak A/S | Actuator |
| EP3233916A4 (en) | 2014-12-19 | 2018-06-06 | Alder Biopharmaceuticals, Inc. | Humanized anti-acth antibodies and use thereof |
| EP3199156A1 (de) | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika |
| EP3480198B1 (en) | 2016-06-30 | 2021-05-05 | Riken | Novel compound or pharmaceutically acceptable salt thereof |
| US11377436B2 (en) | 2017-07-12 | 2022-07-05 | The Brigham And Women's Hospital, Inc. | EAAT2 enhancing molecules |
| SG11202003407VA (en) | 2017-10-17 | 2020-05-28 | Merck Patent Gmbh | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF |
| KR102695210B1 (ko) | 2018-06-05 | 2024-08-13 | 크리네틱스 파마슈티칼스, 인크. | 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도 |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| WO2021091788A1 (en) | 2019-11-07 | 2021-05-14 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| JP7672406B2 (ja) | 2019-12-18 | 2025-05-07 | クリネティックス ファーマシューティカルズ，インク． | Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 |
| JP7651574B2 (ja) | 2019-12-23 | 2025-03-26 | クリネティックス ファーマシューティカルズ，インク． | スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 |
| JP2023537598A (ja) | 2020-08-12 | 2023-09-04 | スプルース バイオサイエンシーズ，インク． | 多嚢胞性卵巣症候群を処置するための方法および組成物 |
| BR112023018816A2 (pt) | 2021-03-19 | 2023-10-31 | Crinetics Pharmaceuticals Inc | Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença |
| WO2023163945A1 (en) | 2022-02-23 | 2023-08-31 | Crinetics Pharmaceuticals, Inc. | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome |
| EP4634176A1 (en) | 2022-12-16 | 2025-10-22 | Crinetics Pharmaceuticals, Inc. | Crystalline melanocortin subtype-2 receptor (mc2r) antagonist |
-
2022
- 2022-03-16 BR BR112023018816A patent/BR112023018816A2/pt unknown
- 2022-03-16 IL IL305952A patent/IL305952A/en unknown
- 2022-03-16 KR KR1020237032584A patent/KR20230159443A/ko active Pending
- 2022-03-16 US US17/696,279 patent/US12280046B2/en active Active
- 2022-03-16 EP EP22772124.8A patent/EP4308553A4/en active Pending
- 2022-03-16 WO PCT/US2022/020543 patent/WO2022197798A1/en not_active Ceased
- 2022-03-16 JP JP2023556949A patent/JP2024510260A/ja active Pending
- 2022-03-16 AU AU2022240609A patent/AU2022240609A1/en active Pending
- 2022-03-16 CA CA3211644A patent/CA3211644A1/en active Pending
- 2022-03-16 TW TW111109708A patent/TWI916531B/zh active
- 2022-03-16 MX MX2023010897A patent/MX2023010897A/es unknown
-
2025
- 2025-03-18 US US19/082,571 patent/US20250367190A1/en active Pending
- 2025-09-22 JP JP2025157498A patent/JP2026009936A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1103589C (zh) | 调节人体性反应的方法 | |
| TWI619505B (zh) | 脫毛症治療劑 | |
| Krasagakis et al. | Management of severe scleroderma with long-term extracorporeal photopheresis | |
| RU2502519C2 (ru) | Терапевтическое средство для лечения ринита | |
| JP2017533972A5 (enExample) | ||
| RU2014113334A (ru) | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний | |
| JP2024500324A5 (enExample) | ||
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| Buckle | Treatment of thyroid crisis by beta-adrenergic blockade | |
| JPH07556B2 (ja) | 間質性膀胱炎に対する治療用医薬組成物 | |
| JP2001526686A (ja) | ヒトの性応答を調節するための組み合わせ治療 | |
| JP2003519181A (ja) | 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物 | |
| BR112020018362A2 (pt) | Composição de glp-1 para tratar obesidade e controle de peso | |
| JP2022058873A5 (enExample) | ||
| JP2017522389A (ja) | シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療 | |
| TAUBENHAUS et al. | Clinical and histological observations on a case of scleroderma treated with cortisone | |
| JP2003509467A (ja) | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療する方法 | |
| JP2001512482A (ja) | レプチン受容体リガンドの拍動性送達 | |
| JP4652689B2 (ja) | 骨再生を促進するカルモジュリンの使用 | |
| TWI850283B (zh) | 用於治療糜爛性手部骨關節炎的孟魯司特 | |
| WO2016014680A2 (en) | Oral transmucosal compositions including aromatase inhibitors for low testoterone levels in men | |
| AU781842B2 (en) | Use of growth hormone (hGH) for the treatment of sexual functional disturbances | |
| JP2024518804A5 (enExample) | ||
| JP2003534237A (ja) | 食欲の抑制又は満腹の惹起のための成長ホルモン又は成長ホルモン分泌促進物質の使用 | |
| JP5667565B2 (ja) | 閉経期、ホルモン変動および関節炎と関連する症状を治療するための組成物および方法 |